TENX — TENAX THERAPEUTICS, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on TENX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-10 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-15 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-07-14 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-09 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-26 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-06-04 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-13 | Giordano Christopher Thomas CEO | Option exercise | 8.5K | 5.94 | 50.5K |
| 2026-07-13 | Giordano Christopher Thomas CEO | Option exercise | 219 | 3.55 | 777 |
| 2026-05-11 | STAAB THOMAS R II Chief Financial Officer | Grant or award | 10.0K | 0.00 | 0 |
| 2025-12-09 | Rich Stuart Chief Medical Officer | Open-market purchase | 2.5K | 10.22 | 25.6K |
| 2025-12-08 | Rich Stuart Chief Medical Officer | Open-market purchase | 2.5K | 10.10 | 25.2K |
| 2025-12-04 | Rich Stuart Chief Medical Officer | Open-market purchase | 2.5K | 9.20 | 23.0K |
| 2025-12-03 | Rich Stuart Chief Medical Officer | Open-market purchase | 1.5K | 9.08 | 13.6K |
| 2025-12-02 | Rich Stuart Chief Medical Officer | Open-market purchase | 1.0K | 9.01 | 9.0K |
| 2025-11-20 | Giordano Christopher Thomas CEO | Open-market purchase | 538 | 7.59 | 4.1K |
| 2025-11-19 | Giordano Christopher Thomas CEO | Open-market purchase | 455 | 7.51 | 3.4K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | 29.1M | 1.8M |
| Venrock Adviser, LLC | 26.8M | 1.7M |
| PERCEPTIVE ADVISORS LLC | 23.2M | 1.4M |
| Ikarian Capital, LLC | 16.3M | 1.0M |
| Stonepine Capital Management, LLC | 15.6M | 975.2K |
| Logos Global Management LP | 10.0M | 625.0K |
| MORGAN STANLEY | 9.5M | 596.6K |
| Velan Capital Investment Management LP | 9.3M | 583.3K |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.6M | 540.1K |
| Point72 Asset Management, L.P. | 8.5M | 534.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G | 2026-08-18 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-12 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky · 2026-08-19
- TENAX THERAPEUTICS, INC. (TENX) filed form SCHEDULE 13G · 2026-08-18 · SEC EDGAR
- Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) · 2026-08-12
Ask the AI about TENX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →